SCHEDULE: StemPoint Capital Discloses 7.0% Stake in Surrozen
Beneficial Ownership Disclosure
StemPoint Capital LP and affiliates have disclosed a 7.0% beneficial ownership stake in Surrozen, Inc., totaling 619,766 shares.
Summary
- StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have jointly filed an Amendment No. 4 to Schedule 13G.
- The Reporting Persons collectively beneficially own 619,766 shares of Surrozen, Inc. Common Stock.
- This ownership represents 7.0% of Surrozen, Inc.'s outstanding Common Stock.
- The total beneficially owned shares consist of 290,108 shares of Common Stock and 329,658 shares issuable upon the exercise of Warrants (Series A, B, and E).
- The percentage of class is calculated based on 8,571,421 shares of Common Stock outstanding as of November 5, 2025, plus the exercisable warrants.
- The Reporting Persons have shared voting power over 573,323 shares and shared dispositive power over 619,766 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral disclosure, typical for reporting significant passive ownership, indicating an investor's position rather than a specific positive or negative event for the company.
Industry Context
StockSavvy.ai notes that a 7.0% stake by an institutional investor like StemPoint Capital in a biotechnology company such as Surrozen, Inc. indicates a significant, non-controlling investment. Such filings often signal an investor's confidence in the company's long-term prospects or a strategic position within the sector, without necessarily implying an activist stance.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing market perception of the stock's stability and institutional interest.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | End of quarterly period for which Surrozen's Form 10-Q was filed |
| 11/05/2025 | Date as of which 8,571,421 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q |
| 11/07/2025 | Date Surrozen's quarterly report on Form 10-Q was filed with the SEC |
| 12/31/2025 | Date of event which requires filing of this statement |
| 02/17/2026 | Filing date of the Schedule 13G Amendment No. 4 |
Keywords
Surrozen Inc, StemPoint Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, SRZN
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.